Cagrilintide Peptide: The Complete Guide - Uses, Mechanism, Dosing, Safety & Research

Quick Facts

What Cagrilintide Does & How It Works

What It Does - Functional Outcomes

• Reduces body weight through sustained appetite suppression and reduced caloric intake
• Suppresses both hunger-driven and reward-driven food seeking - the constant preoccupation with food that many people with obesity describe
• Slows gastric emptying, extending the period of fullness after meals
• Reduces postprandial glucagon release, limiting the blood sugar spikes that follow eating
• Improves glycemic control in people with type 2 diabetes, measured by HbA1c reduction
• Preferentially reduces visceral fat - the metabolically active fat stored around internal organs - while preserving lean body mass
• Produces synergistic weight loss when combined with GLP-1 receptor agonists like semaglutide, by engaging complementary brain circuits that GLP-1 agonists do not reach

How It Works - Mechanism of Action

Amylin and Calcitonin Receptor Activation (Evidence: Human pharmacodynamic studies and knockout animal models)

Cagrilintide is a non-selective agonist at all three amylin receptor subtypes (AMY1R, AMY2R, and AMY3R) as well as the calcitonin receptor (CTR) directly. Amylin receptors are built from two components: a calcitonin receptor paired with one of three receptor activity-modifying proteins (RAMPs 1, 2, and 3). Cagrilintide activates all four receptor combinations with EC50 values in the nanomolar range, meaning it triggers a response at very low concentrations. Knockout animal studies confirmed that both AMY1R and AMY3R are required for the compound's full weight-reducing effect - removing either receptor substantially diminishes the outcome.

Central Appetite Suppression - Homeostatic and Hedonic Circuits (Evidence: Human pharmacodynamic data and animal neuroanatomy studies)

Receptor activation in the brain occurs primarily in three hindbrain regions: the area postrema (a sensory region where the blood-brain barrier is naturally permeable), the nucleus tractus solitarius (the brain's primary satiety processing center), and the lateral parabrachial nucleus (which relays satiety signals forward to the hypothalamus). These regions govern both homeostatic appetite - eating based on actual energy need - and hedonic appetite - eating driven by reward, habit, and food preoccupation. GLP-1 receptor agonists primarily target hypothalamic homeostatic circuits, which is the mechanistic reason these two compound classes are genuinely complementary rather than redundant when combined.

Gastric Emptying Delay via Independent Neural Mechanism (Evidence: Human pharmacodynamic and preclinical data)

Cagrilintide slows the rate at which the stomach empties its contents into the small intestine, extending the duration of postprandial fullness and slowing nutrient absorption. The neural pathway responsible for this effect is distinct from the pathway through which GLP-1 receptor agonists achieve the same result. When cagrilintide is combined with semaglutide, the gastric-emptying delay from two independent neural mechanisms may be additive - which contributes to the combination's superior appetite suppression profile.

Postprandial Glucagon Suppression (Evidence: Human clinical data)

Cagrilintide reduces the release of glucagon from pancreatic alpha cells following meals. Glucagon is the hormone that signals the liver to release stored glucose into the bloodstream - suppressing it limits postprandial blood sugar rises and reduces subsequent fat storage from glucagon-mediated metabolic effects. This mechanism is distinct from GLP-1-mediated glucagon suppression, operating through different pancreatic feedback pathways, and contributes to the superior glycemic outcomes seen with CagriSema compared to either compound alone in type 2 diabetes populations.

Albumin-Binding Pharmacokinetic Extension (Evidence: Human pharmacokinetic studies)

The C20 fatty diacid modification attached to cagrilintide's N-terminus binds reversibly to serum albumin - the most abundant protein in blood plasma. This creates a circulating reservoir that releases active peptide slowly over time, extending the effective half-life from the minutes that native amylin persists to approximately eight days. The modification also protects the peptide from rapid renal clearance. The pharmacokinetics are linear and dose-proportional across the studied clinical range, meaning higher doses produce proportionally higher and predictable plasma concentrations.

Cagrilintide Molecular Profile

Structure reference: View on PubChem - Publishing team: retrieve 2D structure image from this link.

Cagrilintide Uses & Benefits

Obesity and Overweight Management

Cagrilintide is primarily researched as a treatment for obesity and overweight in adults. Users and researchers target it for sustained body weight reduction through appetite suppression and reduced caloric intake, operating through amylin and calcitonin receptor pathways that are mechanistically independent from GLP-1 agonists. Phase 2 data confirmed dose-dependent weight reduction across five dose levels, and Phase 3 data from the REDEFINE 1 trial established 11.5% mean weight loss at 2.4 mg over 68 weeks as a monotherapy - comparable to some approved weight-loss medications and surpassing liraglutide 3.0 mg at the highest studied dose. (Evidence: Strong - Garvey et al., NEJM, 2025)

Combination Weight Loss Therapy - CagriSema

The most studied application of cagrilintide is in combination with semaglutide (GLP-1 receptor agonist), a pairing known as CagriSema. The rationale is mechanistic: cagrilintide targets hindbrain amylin and calcitonin receptors while semaglutide targets hypothalamic GLP-1 receptors - engaging two anatomically distinct appetite circuits simultaneously. REDEFINE 1 Phase 3a data from 3,417 participants across 22 countries showed CagriSema achieving a mean 20.4% body weight reduction over 68 weeks, versus 14.9% for semaglutide alone and 11.5% for cagrilintide alone. (Evidence: Strong - Garvey et al., NEJM, 2025)

Type 2 Diabetes - Glycemic Control and Weight Management

In type 2 diabetes populations, cagrilintide is studied both as a standalone glycemic agent and in combination with semaglutide. Its glucagon-suppressing mechanism complements GLP-1-mediated insulin secretion stimulation, addressing postprandial glucose elevation through a different pathway. The Phase 2 Frias et al. (2023) study showed CagriSema achieving a mean HbA1c reduction of 2.2 percentage points over 32 weeks, compared to 1.8 for semaglutide alone and 0.9 for cagrilintide alone - with superior weight loss for the combination versus either monotherapy. (Evidence: Strong - Frias et al., Lancet, 2023)

Visceral Fat Reduction and Body Composition

Clinical imaging data from Phase 2 and Phase 3 trials documents preferential reduction of visceral adiposity - the fat stored around internal organs that carries the greatest metabolic risk - relative to total body weight reduction. Lean mass preservation is supported by preclinical data and is consistent with available human data, though full body composition analysis from the Phase 3 trials is not yet completely published. This body composition profile - fat loss with lean mass sparing - distinguishes cagrilintide from older weight-loss approaches that reduce lean mass alongside fat. (Evidence: Moderate - human imaging data from clinical trials; full body composition data pending)

Metabolic Syndrome and Cardiometabolic Risk Reduction

Cagrilintide's effects on body weight, visceral fat, blood glucose, and postprandial glucagon collectively address multiple components of metabolic syndrome. Waist circumference reduction - a validated proxy for visceral adiposity and cardiometabolic risk - was among the largest documented for any treatment in a meta-analysis covering three RCTs with 3,545 total participants. The compound is not formally studied as a cardiometabolic risk reduction agent in isolation, but the mechanistic basis for risk reduction through its combined effects on weight, glucose, and fat distribution is supported by the existing evidence base. (Evidence: Moderate - indirect data from weight and glycemic outcomes in clinical trials)

Where This Guide Comes From

Cagrilintide Results & Timelines

Weight Loss and Appetite Suppression

• Week 1-2: Appetite suppression is often the first reported effect - reduced hunger, smaller portion satisfaction, and decreased food preoccupation typically appear before measurable weight changes. Some people notice reduced cravings for high-fat or high-sugar foods specifically.
• Week 3-6: Measurable body weight change begins accumulating. Published Phase 2 data shows dose-dependent weight reduction emerging clearly by the four-to-six week mark at therapeutic doses, with the pace of loss correlated with dose level.
• Week 8-16: The middle phase of weight loss, where the effects are typically most pronounced relative to the trajectory. Gradual dose escalation protocols reach target doses in this window, and the appetite effects stabilize at the maintenance dose level.
• Week 20-26: Phase 2 monotherapy data shows approximately 10% mean weight loss at 26 weeks at the 2.4 mg dose. Individual variation at this point is significant - some participants achieve substantially more, others less, depending on diet, activity, and metabolic starting point.
• Beyond 26 weeks: Phase 3 REDEFINE 1 data shows continued weight loss progression through 68 weeks, with the 2.4 mg monotherapy group reaching 11.5% mean reduction by end of study. The CagriSema combination continues accumulating weight loss through the full 68-week period, reaching 20.4% mean reduction.

Glycemic Control (Type 2 Diabetes Populations)

• Week 4-8: Early reductions in postprandial glucose are typically detectable in people with type 2 diabetes at therapeutic doses, reflecting the glucagon-suppressing mechanism.
• Week 12-16: HbA1c - a three-month average blood glucose marker - begins reflecting cumulative improvement. The Phase 2 Frias et al. data shows the trajectory of HbA1c reduction continues through the full 32-week study duration.
• Week 20-32: CagriSema achieves a mean HbA1c reduction of 2.2 percentage points by 32 weeks in the Frias et al. Phase 2 data - a clinically meaningful reduction that exceeds both monotherapies.

How to Administer Cagrilintide

Subcutaneous Injection (SubQ)

Subcutaneous injection is the only documented administration route for cagrilintide. All published Phase 1b, Phase 2, and Phase 3 clinical research used subcutaneous injection exclusively, consistent with the compound's design as a lipidated peptide requiring depot-forming slow absorption from subcutaneous tissue. Common injection sites in clinical protocols include the abdomen, thigh, and upper arm - sites with sufficient subcutaneous fat for consistent absorption. The once-weekly dosing schedule aligns directly with the approximately 180-hour plasma half-life.

Intramuscular Injection (IM)

Intramuscular administration has not been studied for cagrilintide. The compound's pharmacokinetic profile - designed around slow subcutaneous absorption into the albumin-binding reservoir - is optimized for the subcutaneous route. IM injection is not documented in any published protocol and offers no pharmacokinetic rationale for this compound.

Oral

Oral administration is not viable for cagrilintide. As a 37-amino-acid peptide with a molecular weight of approximately 4,409 g/mol, cagrilintide would be broken down by gastric acid and digestive enzymes well before meaningful absorption could occur. No oral formulation has been studied or proposed. All research is subcutaneous injection only.

Cagrilintide Dosage & Cycle Length

Overall dosing range: 0.3 mg to 4.5 mg per week via subcutaneous injection - range studied in Phase 2 dose-finding trials; 2.4 mg per week is the dose used in Phase 3 trials for both monotherapy and combination protocols

How the goal shifts where you land:

• Low end of range (0.3-0.6 mg/week): Associated with early dose-escalation phases and tolerability assessment in clinical protocols; weight loss responses at these doses are more modest but GI side effect burden is lower
• Mid range (1.2-2.4 mg/week): The primary therapeutic range in published research; 2.4 mg per week is the dose used in all Phase 3 trials and delivers approximately 10-11.5% body weight reduction as monotherapy over 26-68 weeks
• High end of range (4.5 mg/week): Studied in Phase 2 dose-finding; produced 10.8% weight loss at 26 weeks - marginally greater than 2.4 mg - with a higher incidence of gastrointestinal adverse events; this dose was not carried forward into Phase 3 trials, with 2.4 mg selected as the optimal balance of efficacy and tolerability (Evidence: Strong - Phase 2 dose-finding data)

Frequency: Once weekly - all published clinical research used weekly subcutaneous injection, consistent with the approximately 180-hour plasma half-life

Cycle length: 20 weeks (Phase 1b), 26 weeks (Phase 2), and 68 weeks (Phase 3) in published clinical protocols; no defined cycle-and-break pattern has been studied - clinical data treats cagrilintide as a continuous therapy rather than a cyclical compound

Dose escalation: Phase 2 and Phase 3 trial protocols incorporated gradual dose escalation over several weeks before reaching target doses. This escalation approach is standard practice with this class of compound and is associated with improved GI tolerability during the initiation period. Specific escalation steps used in clinical protocols are documented in the published trial methods.

Combination dosing (CagriSema): In all published combination research, cagrilintide 2.4 mg and semaglutide 2.4 mg were administered together once weekly. Phase 3 data shows this combination delivers a mean 20.4% body weight reduction over 68 weeks in people without diabetes.

Cagrilintide Vial Sizes, Costs & Quality

Common vial sizes: 2 mg and 5 mg vials are the sizes most commonly available through U.S.-based research peptide manufacturers for cagrilintide; some suppliers offer 10 mg vials

Typical cost range: $80-$160 per vial for U.S.-manufactured research-grade cagrilintide at current market pricing - varies by supplier, vial size, and purity tier; larger vial sizes typically reduce per-milligram cost

Storage - lyophilized (dry powder):

• Temperature: -20 degrees C for long-term storage; some manufacturers specify stability at 4 degrees C for short-term storage of up to several weeks
• Shelf life: Typically 12-24 months from manufacture when stored correctly at -20 degrees C
• Light sensitivity: Protect from light; store in original sealed vial

Storage - reconstituted (in solution):

• Temperature: Refrigerate at 2-8 degrees C; do not freeze reconstituted solution
• Use window: Typically 28-30 days once reconstituted, when stored properly at 2-8 degrees C

Normal appearance after reconstitution: Cagrilintide dissolves into a clear, colorless to very slightly yellowish solution after reconstitution. Some mild turbidity immediately after reconstitution is not unusual and typically clears with gentle swirling - do not shake vigorously. The lipidated structure of the molecule can influence dissolution behavior; if the solution does not fully clarify with gentle mixing, check that the diluent temperature and the vial temperature are aligned.

Signs of degradation: Heavy cloudiness that does not resolve with gentle swirling, visible particulates or chunks, significant discoloration beyond a very faint tint, or unusual odor are indicators that the solution should not be used. Peptide that has been left at room temperature for extended periods or exposed to repeated freeze-thaw cycles should be discarded.

Quality Considerations

Cagrilintide is a structurally complex lipidated peptide - 37 amino acids with a C20 fatty diacid modification, three proline substitutions, three specific amino acid substitutions, and a disulfide bridge that must form correctly to produce an active molecule. Every one of those features costs something to get right, and when pricing undercuts what synthesis and verification of that structure actually costs, something in the process got skipped. The most common cuts are in purification depth (HPLC-grade purity versus crude synthesis) and third-party testing - a vial might contain the right sequence but at 70% purity rather than the 99%+ that verified, tested product carries. Most of what is sold online through unverified overseas sources has no certificate of analysis, no documented chain of custody, and no way to confirm what concentration or purity is actually in the vial. U.S.-manufactured research peptides carry documented synthesis standards, verifiable certificates of analysis from independent labs, and traceability from synthesis through shipment - which matters considerably when you are working with a compound this structurally complex.

Cagrilintide Side Effects & Safety

Side Effect Spectrum

Contraindications

• Personal or family history of medullary thyroid carcinoma (MTC): Calcitonin receptor agonism is mechanistically relevant to the MTC signal seen with GLP-1/calcitonin-pathway compounds; this contraindication carries over by mechanism even though direct cagrilintide data is limited
• Multiple endocrine neoplasia type 2 (MEN2): Same rationale as MTC; receptor profile warrants caution in this population
• Known hypersensitivity to cagrilintide or any component of its formulation: Standard contraindication; anaphylactic or allergic reactions would preclude use
• Insufficient data to confirm safety in people with severe renal or hepatic impairment; the compound's metabolic pathways involve both renal and hepatic elimination routes and have not been specifically studied in these populations

Populations Where Caution Is Warranted

• Pregnancy and breastfeeding: No safety data exists for cagrilintide in pregnancy or lactation; use is not appropriate without medical supervision and is generally not recommended given the complete absence of safety data
• Pediatric use: Not studied in pediatric populations; not appropriate without medical supervision
• History of pancreatitis: Theoretical concern with compounds that affect gastric emptying and GI motility; insufficient cagrilintide-specific data to quantify risk
• People on insulin or sulfonylureas: Additive glucagon suppression and weight loss effects can increase hypoglycemia risk in combination with insulin-stimulating agents; blood glucose monitoring is warranted
• People with gastroparesis or significant GI motility disorders: Gastric emptying delay is a direct pharmacodynamic effect of cagrilintide; this mechanism may worsen existing motility impairment

Red Flags - Stop Use and Seek Medical Attention If:

• Severe, persistent abdominal pain - particularly radiating to the back - which may indicate pancreatitis
• Signs of allergic reaction: rash, difficulty breathing, swelling of the face or throat, rapid heartbeat
• Persistent severe vomiting that prevents adequate fluid intake (dehydration risk)
• Significant symptoms of hypoglycemia in people using insulin or insulin secretagogues alongside cagrilintide
• Severe injection-site reactions that do not resolve - hardening, significant swelling, or signs of infection at injection sites

Drug and Compound Interactions

No formal drug interaction studies have been published for cagrilintide in isolation. The most clinically relevant potential interaction is with insulin and sulfonylureas, where cagrilintide's glucagon-suppressing effect adds to glucose-lowering mechanisms, increasing hypoglycemia risk. When used as CagriSema (with semaglutide), the additive gastric-emptying delay from two independent neural mechanisms may affect the absorption timing of oral medications taken with food - a consideration documented broadly with GLP-1 receptor agonists that would logically extend to this combination. Anti-drug antibodies were detected in some trial participants across multiple studies, though no impact on efficacy or safety outcomes was observed in published data.

Cagrilintide Research & Studies

Pharmacokinetics & Metabolism

Absorption & Bioavailability Cagrilintide is absorbed slowly after subcutaneous injection, reaching peak plasma concentration (tmax) at a median of 24 to 72 hours across the studied dose range of 0.16 to 4.5 mg. Pharmacokinetics are dose-proportional and linear - area under the curve (AUC) increases consistently with dose, which means the body handles higher doses predictably rather than saturating the system. Specific subcutaneous bioavailability fraction data is not reported in the available literature.

Distribution Cagrilintide distributes throughout the body via albumin-mediated transport. Because albumin circulates throughout virtually all tissues, this distribution mechanism provides access to amylin receptor-expressing regions including the hindbrain, brainstem nuclei, and peripheral tissues. The compound does not require blood-brain barrier crossing to reach its primary central targets - the area postrema and adjacent structures sit in a circumventricular region where the barrier is naturally permeable, meaning blood-borne compounds can reach neurons there directly.

Half-Life Plasma half-life in human clinical studies ranges from 159 to 195 hours, with a confirmed approximate value of 180 hours (roughly eight days). At the 2.4 mg dose specifically, half-life was measured at approximately 184 hours. This half-life is entirely a function of the albumin-binding lipidation modification - without it, native amylin clears in minutes.

Metabolism & Elimination Cagrilintide is metabolized through two primary pathways: proteolytic cleavage of the peptide backbone by peptidases, and sequential beta-oxidation of the C20 fatty diacid side chain. Resulting metabolites are eliminated via both renal and hepatic routes. No accumulation was observed in multi-dose studies, and clearance parameters remained consistent across all dose groups studied.

Note on data quality: All pharmacokinetic data comes from human clinical studies. Data for populations with severe renal or hepatic impairment is not available.

Mechanistic Research

Amylin and Calcitonin Receptor Activation Pattern (Evidence: Human pharmacological studies and knockout animal models)

Cagrilintide activates all three amylin receptor subtypes (AMY1R, AMY2R, AMY3R) and the calcitonin receptor (CTR) directly, with EC50 values in the nanomolar range. Knockout studies in rodent models confirmed that AMY1R and AMY3R are both required for the compound's full weight-reducing effects - mice lacking RAMP1 or RAMP3 (the proteins that define AMY1R and AMY3R respectively) showed substantially diminished neuronal activation in the area postrema, nucleus tractus solitarius, and lateral parabrachial nucleus, measured by reduced cFos expression in those regions.

Complementary Brain Circuit Engagement vs. GLP-1 Agonists (Evidence: Human pharmacodynamic data and animal neuroanatomy studies)

GLP-1 receptor agonists like semaglutide primarily suppress appetite through the hypothalamic arcuate nucleus - the homeostatic energy balance center. Cagrilintide operates primarily in the hindbrain through the area postrema and nucleus tractus solitarius, with downstream projections to the lateral parabrachial nucleus. This anatomical separation means the two pathways are genuinely complementary rather than redundant. The synergistic weight loss seen with CagriSema in clinical trials - 20.4% versus 14.9% for semaglutide alone and 11.5% for cagrilintide alone in REDEFINE 1 - reflects this complementarity directly. (Evidence: Strong - Garvey et al., NEJM, 2025)

Cryo-EM Structural Data (2025) (Evidence: In vitro structural biology)

A 2025 publication in Nature Communications characterized cagrilintide's binding interactions with calcitonin and amylin receptors using cryo-electron microscopy. The structural data reveals distinct receptor binding geometry and signaling kinetics compared to salmon calcitonin - the most commonly used CTR reference compound. These structural differences correlate with cagrilintide's reduced tendency to cause receptor downregulation compared to salmon calcitonin, providing a molecular explanation for why cagrilintide maintains sustained efficacy rather than developing tolerance over time.

Condition-Focused Research

Obesity and Overweight - Monotherapy Evidence {#research-obesity}

The Phase 2 dose-finding trial (Lau et al., 2021) enrolled adults with overweight or obesity across multiple centers and tested cagrilintide at five doses (0.3, 0.6, 1.2, 2.4, and 4.5 mg weekly) against placebo and active comparator liraglutide 3.0 mg over 26 weeks. Dose-dependent body weight reduction was confirmed across all dose levels. At 4.5 mg, cagrilintide produced 10.8% mean weight loss versus 3.0% placebo and 9.0% liraglutide - a statistically significant superiority over liraglutide at the highest dose (estimated treatment difference +1.8%, p=0.03). The REDEFINE 1 Phase 3a trial (Garvey et al., 2025) extended the monotherapy picture to 68 weeks, showing 11.5% mean weight reduction at 2.4 mg in 3,417 participants across 22 countries. (Evidence: Strong - Lau et al., Lancet, 2021; Garvey et al., NEJM, 2025)

Obesity and Overweight - CagriSema Combination Evidence {#research-cagrissema}

The REDEFINE 1 trial is the landmark combination study. Among 3,417 adults without diabetes (BMI 30 or higher, or BMI 27 or higher with an obesity-related complication), CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg, once weekly) achieved a mean 20.4% body weight reduction over 68 weeks versus 14.9% for semaglutide alone, 11.5% for cagrilintide alone, and 3.0% for placebo. The proportion achieving at least 25% body weight reduction was substantially higher for CagriSema than for semaglutide. 91.9% of CagriSema participants achieved at least 5% body weight reduction versus 31.5% of placebo. The Phase 1b study (Enebo et al., 2021) that established the combination concept showed -15.6% weight reduction at 20 weeks versus -8.2% placebo. (Evidence: Strong - Garvey et al., NEJM, 2025; Enebo et al., Lancet, 2021)

Type 2 Diabetes - Glycemic and Weight Outcomes {#research-t2d}

The Phase 2 study by Frias et al. (2023) enrolled adults with type 2 diabetes managed on metformin, with or without SGLT2 inhibitors. Over 32 weeks, CagriSema achieved a mean HbA1c reduction of 2.2 percentage points versus 1.8 for semaglutide alone and 0.9 for cagrilintide alone - with body weight reductions superior to either monotherapy. The REIMAGINE 2 trial extended this picture to 68 weeks in a type 2 diabetes population, showing CagriSema achieving 17.1% weight loss versus 9.8% for semaglutide monotherapy (estimated treatment difference -7.3%, 95% CI -11.2% to -3.5%). (Evidence: Strong - Frias et al., Lancet, 2023)

Body Composition - Visceral Fat and Lean Mass {#research-composition}

Clinical imaging data from Phase 2 and Phase 3 trials documents preferential reduction of visceral adiposity relative to total body fat reduction. Lean mass preservation was confirmed in preclinical models and is consistent with available human data, though detailed body composition analysis from the Phase 3 trials is not yet fully published as of early 2026. A meta-analysis covering three RCTs with 3,545 total participants found that CagriSema produced the largest reductions in both body weight and waist circumference among treatments analyzed - waist circumference being a validated proxy for visceral adiposity. (Evidence: Moderate - clinical imaging from human trials; full body composition data pending Phase 3 publication)

Safety & Tolerability Research

Across published Phase 1b, Phase 2, and Phase 3 trials, the most consistent finding is that gastrointestinal adverse events are common but predominantly mild to moderate and transient. In REDEFINE 1, GI adverse events were reported in 79.6% of CagriSema participants versus 39.9% of placebo - a substantial difference, though the majority resolved without discontinuation. Phase 2 monotherapy data suggested that cagrilintide as a standalone compound produced lower rates of vomiting than semaglutide in comparative analyses. Anti-drug antibody development was detected in a subset of participants across multiple trials; no impact on efficacy or safety outcomes was demonstrated in available data, though long-term immunogenicity implications require continued monitoring. No signals for medullary thyroid carcinoma, pancreatitis, or other serious class-effect concerns have emerged in available trial data; however, the longest published trial duration of 68 weeks is insufficient to characterize rare long-term risks.

Research Limitations

Cagrilintide's research base is among the strongest of any investigational peptide, but meaningful gaps remain. Study populations in completed trials are predominantly White women, which limits generalizability across diverse populations and body types. The longest published trial duration is 68 weeks - weight maintenance, safety, and efficacy beyond that window are not yet established in controlled data. Cagrilintide monotherapy data is substantially thinner than combination data, as the development trajectory has prioritized the CagriSema combination; the independent dose-response picture is therefore less fully characterized. Pharmacokinetic data in people with significant renal or hepatic impairment is absent. Long-term immunogenicity implications of anti-drug antibody development remain uncharacterized beyond the 68-week trial window.

Is Cagrilintide Legal? Regulatory & Sports Status

FDA status: Cagrilintide is an investigational compound with no FDA approval for any indication as of July 2026. It is not available through licensed compounding pharmacies - investigational compounds that are not FDA-approved and not on the 503A/503B compounding-eligible drug lists cannot be legally compounded in the United States. Novo Nordisk has submitted regulatory applications for CagriSema (cagrilintide plus semaglutide as a combination product) based on Phase 3 REDEFINE trial data; regulatory review timelines are not confirmed in available data.

Research Use Only (RUO): In the United States and most jurisdictions, cagrilintide is classified as a research compound and is not approved for human therapeutic use. Commercial research peptide manufacturers sell it under research use designations.

WADA / USADA status: Cagrilintide does not appear on the current WADA Prohibited List as of the 2025/2026 list. However, peptide hormones, growth factors, and related compounds are broadly regulated under WADA, and compounds with activity at calcitonin receptors or that produce physiological effects relevant to sport may be subject to future listing decisions. Athletes subject to anti-doping rules should consult current WADA documentation directly - regulatory frameworks evolve and this guide reflects status as of July 2026.

Country-specific notes: Regulatory status varies by jurisdiction. In the European Union, cagrilintide is similarly investigational, with the EMA reviewing the CagriSema combination product application in parallel with FDA review. In Australia, Canada, and the United Kingdom, the compound is not approved and would require equivalent prescription-pathway regulatory clearance that does not yet exist. Users in any jurisdiction are responsible for verifying the current legal status in their location.

Detection: No validated anti-doping detection test for cagrilintide has been publicly documented. The compound's long half-life - approximately eight days - would, in principle, provide a detection window of several weeks after last use if a test were developed.

Cagrilintide vs. Alternatives

Commonly Paired With - Synergistic Stacks

• Cagrilintide + Semaglutide (CagriSema): This is the most extensively studied combination in weight-loss research. The two compounds engage complementary, anatomically distinct brain appetite circuits - cagrilintide in the hindbrain via amylin and calcitonin receptors, semaglutide in the hypothalamus via GLP-1 receptors - producing synergistic rather than redundant effects. Phase 3 REDEFINE 1 data shows 20.4% mean weight loss with the combination versus 14.9% for semaglutide alone and 11.5% for cagrilintide alone.
• Cagrilintide + Retatrutide: A research combination pairing cagrilintide's amylin and calcitonin pathway activation with retatrutide's triple GLP-1, GIP, and glucagon receptor agonism. Published Phase 3 data for this combination does not yet exist; it remains in earlier research stages.
• Stacking information is for educational context - individualized stack protocols live inside MPP.

Alternatives - When Another Peptide May Be Considered

Semaglutide (Ozempic / Wegovy) Semaglutide is the most studied GLP-1 receptor agonist and the compound most directly compared to cagrilintide. Someone might choose semaglutide over cagrilintide when seeking a compound with an established regulatory approval pathway for obesity (Wegovy) and a larger long-term safety dataset, or when access to the CagriSema combination is not available. Semaglutide produces approximately 14.9% mean weight loss at 2.4 mg over 68 weeks as a monotherapy, compared to cagrilintide's 11.5%.

Retatrutide Retatrutide is a triple agonist at GLP-1, GIP, and glucagon receptors - a mechanistically distinct approach that has shown weight loss approaching 24% in Phase 2 data. Someone might consider retatrutide over cagrilintide when maximizing weight loss as a monotherapy is the priority. Unlike cagrilintide, retatrutide does not target amylin or calcitonin receptors, meaning the two compounds are genuinely complementary rather than substitutable.

Tirzepatide (Mounjaro / Zepbound) Tirzepatide is an approved dual GLP-1 and GIP receptor agonist with Phase 3 data showing 20-22% mean weight loss as a monotherapy. It offers both greater potency within the incretin pathway and FDA approval for type 2 diabetes and obesity - a regulatory profile that cagrilintide does not yet have. Someone might prefer tirzepatide when regulatory status and prescription access matter, or when GIP receptor engagement is specifically relevant to their goals.

Pramlintide (Symlin) Pramlintide is the only approved amylin analog and cagrilintide's closest mechanistic predecessor. It requires multiple daily injections due to its short half-life, compared to cagrilintide's once-weekly schedule. Weight loss outcomes with pramlintide are modest - primarily studied as an adjunct to insulin in type 1 and type 2 diabetes. Someone already managing diabetes with an established pramlintide protocol might be the rare case where this older compound is preferred based on familiarity and established access.

Comparison table:

Build Your Protocol - MPP CTA

FAQs

What is cagrilintide?

Cagrilintide is a long-acting synthetic analog of amylin - a hormone naturally released by the pancreas alongside insulin after meals - engineered by Novo Nordisk to have a plasma half-life of approximately eight days, enabling once-weekly subcutaneous injection. It is classified as a non-selective agonist at amylin receptor subtypes (AMY1R, AMY2R, AMY3R) and the calcitonin receptor. It is currently an investigational compound with no regulatory approval for human use in any jurisdiction.

What does cagrilintide do?

Cagrilintide primarily reduces body weight by suppressing appetite through amylin and calcitonin receptor signaling in brain regions that control both hunger and reward-driven eating. It also slows gastric emptying, suppresses postprandial glucagon release, and produces preferential reduction of visceral fat while preserving lean mass. In type 2 diabetes populations, it improves glycemic control as measured by HbA1c reductions.

How long does cagrilintide take to work?

Appetite suppression effects are typically reported within the first one to two weeks at therapeutic doses, with measurable body weight changes accumulating over the following weeks. Published Phase 2 data shows approximately 10% mean weight loss by 26 weeks as a monotherapy; Phase 3 combination data with semaglutide shows continued weight loss progression through 68 weeks. Individual timelines vary significantly based on dose, diet, activity, and metabolic starting point.

What is the typical dose of cagrilintide?

Published clinical trials studied cagrilintide at doses ranging from 0.3 mg to 4.5 mg per week via subcutaneous injection. The 2.4 mg per week dose was selected for Phase 3 trials as the optimal balance of efficacy and tolerability and is the primary reference dose in current research. Clinical protocols incorporate gradual dose escalation over several weeks before reaching the target dose. Individual protocols vary and depend on health status, goals, and concurrent compounds.

Is cagrilintide legal?

Cagrilintide is an investigational compound not approved for human use in any jurisdiction as of July 2026. In the United States and most countries, it is classified as a research compound available under research-use designations. It is not eligible for pharmaceutical compounding in the United States. It does not currently appear on the WADA Prohibited List, but athletes subject to anti-doping rules should verify current WADA documentation directly. Users are responsible for understanding applicable laws in their location.

Can cagrilintide be taken orally?

No - cagrilintide is not viable for oral administration. As a 37-amino-acid peptide with a molecular weight of approximately 4,409 g/mol, it would be broken down by gastric acid and digestive enzymes before meaningful absorption could occur. All published research uses subcutaneous injection exclusively, and no oral formulation has been studied or proposed for this compound.

Is cagrilintide the same as CagriSema?

No - cagrilintide and CagriSema are related but distinct. Cagrilintide is a single compound: a long-acting amylin analog. CagriSema is the name for the combination of cagrilintide plus semaglutide (a GLP-1 receptor agonist) administered together as a weekly injection. Most of the Phase 3 clinical trial data - including the REDEFINE 1 trial showing 20.4% mean weight loss - refers to CagriSema as the combination product, not cagrilintide alone. Cagrilintide as a monotherapy produces approximately 11.5% weight loss at 2.4 mg over 68 weeks.

How does cagrilintide differ from semaglutide?

Cagrilintide and semaglutide work through entirely different receptor systems. Semaglutide activates GLP-1 receptors in the hypothalamus and stimulates insulin secretion in a glucose-dependent manner - it is an incretin-pathway compound. Cagrilintide activates amylin and calcitonin receptors primarily in the hindbrain and does not directly stimulate insulin secretion - it is incretin-independent. This anatomical and mechanistic separation is why the combination produces synergistic rather than merely additive weight loss, and why cagrilintide is a complement to semaglutide rather than a replacement for it.

What is the difference between cagrilintide and pramlintide?

Both are amylin analogs, but they are substantially different in practice. Pramlintide (Symlin) is an approved amylin analog with a half-life of a few hours, requiring multiple daily injections and primarily used as an adjunct to insulin in diabetes management. Cagrilintide was engineered specifically to overcome pramlintide's limitations - its albumin-binding lipidation extends the half-life to approximately eight days (once-weekly dosing), and its structural modifications enable non-selective activation of both amylin and calcitonin receptors, producing substantially greater weight loss than pramlintide achieves.

Does cagrilintide require refrigeration?

Lyophilized (powder) cagrilintide should be stored at -20 degrees C for long-term stability, protected from light in a sealed vial. Once reconstituted, the solution should be refrigerated at 2-8 degrees C and used within approximately 28-30 days. Reconstituted cagrilintide should not be frozen. Extended storage at room temperature or exposure to repeated freeze-thaw cycles degrades the compound and the solution should be discarded if storage conditions were not maintained.

Final Thoughts

Cagrilintide occupies an unusual position in the peptide research landscape: it is an investigational compound backed by some of the most rigorous clinical evidence of any compound currently in this space. Multiple Phase 2 and Phase 3 human randomized controlled trials, published in the New England Journal of Medicine and the Lancet, consistently show meaningful weight loss as a monotherapy and substantially greater weight loss when combined with semaglutide. The 20.4% mean body weight reduction achieved by CagriSema in REDEFINE 1 represents the largest sustained weight loss documented in a Phase 3 trial for any injected compound published to date. The mechanism is well-characterized, the pharmacokinetics are linear and predictable, and the evidence base continues to grow.

That said, the picture has important edges. The compound remains unapproved for human use, ineligible for pharmaceutical compounding in the United States, and accessible only as a research compound outside the prescription system. Gastrointestinal side effects are common - affecting the substantial majority of CagriSema users in Phase 3 data - even if most are mild to moderate and transient. Long-term safety data beyond 68 weeks does not yet exist in the published literature. And the study populations, while large, have been predominantly White women, which limits how confidently the findings translate across diverse groups. Anyone working with this compound should understand both what the evidence shows and what it does not yet show.

For those exploring cagrilintide seriously, the most consequential decisions are not which dose to start at - they are whether the compound is appropriate given individual health context, what concurrent medications or compounds are in the picture, and how the protocol is structured and monitored over time. Those are questions that deserve a personalized answer. MyPeptidePal builds individualized protocol frameworks around your specific situation, drawing on the same research base that informs this guide but applied to your goals, your health history, and your starting point. The evidence on cagrilintide is genuinely compelling - and getting the most from it requires more than a general dosing range.

References

1. Lau, D. C. W., et al. (2021). Once-weekly cagrilintide for weight management in adults with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet, 398(10317), 2160-2172.

2. Frias, J. P., et al. (2023). Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet, 402(10398), 720-730.

3. Garvey, W. T., et al. (2025). Cagrilintide and semaglutide for weight management in adults without type 2 diabetes (REDEFINE 1): a double-blind, randomised, placebo- and active-controlled, phase 3a trial. New England Journal of Medicine, 393(7), 635-647.

4. Enebo, L. B., et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet, 397(10286), 1736-1748.

5. Kruse, T., et al. (2021). Designing a dual amylin and calcitonin receptor agonist (DACRA) for improved weight loss and metabolic control: discovery and pharmacology of cagrilintide. Journal of Medicinal Chemistry, 64(15), 11183-11194.